EGFR and neoplasm: As shown in the relationship between small EGFR-TKI and EGFR mutation [40], the ability of TAE226 to compete with ATP, resulting in its anti-tumor potential, is determined by two factors: 1) the binding ability for TAE226 to mutant EGFR and 2) the affinity for ATP to mutant EGFR.